Trial Profile
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Canakinumab in Combination With Docetaxel Versus Placebo in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) Previously Treated With PD-(L)1 Inhibitors and Platinum-based Chemotherapy (CANOPY 2)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary) ; Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CANOPY-2
- Sponsors Novartis; Novartis Pharmaceuticals
- 01 Mar 2024 Results assessing efficacy/safety of canakinumab versus placebo in patients with advanced non-small cell lung cancer (NSCLC) who had progressed after platinum-based doublet chemotherapy (PDC) and immunotherapy published in the Lung Cancer
- 02 Sep 2022 Status changed from completed to discontinued. The study was early terminated due to the lack of efficacy of study treatment observed in the analysis of the primary endpoint of the randomized part.
- 09 Mar 2022 This trial has been discontinued in Poland (End Date: 20 Dec 2021), according to European Clinical Trials Database record.